Jiaxin Yan

TL;DR: Intravenous transplantation of hUC-MSCs is a safe and effective method that can be considered a salvage and priority treatment option for severe COVID-19.

TL;DR: Clinical characteristics and potential risk factors of patients with coronavirus disease 2019 (COVID‐19) in Wuhan Stadium Cabin Hospital could help clinicians to identify patients with poor prognosis at an early stage, and provide early warning role for timely intervention.

TL;DR: In this article, a three-month follow-up study was conducted to assess the safety of human umbilical cord mesenchymal stromal cells (hUC-MSC) therapy and the health-related quality of life (HRQL) of these patients.

TL;DR: Covid-19 is a highly infectious disease, and mostly are middle-aged and elderly cases, there is no significant difference between males and females, and blood tests suggest that white blood cells are most normal and lymphocytes are reduced, C-reactive protein is slightly elevated, and imaging findings are of guiding significance for diagnosis of the disease and therapeutic effect.

TL;DR: Wang et al. as mentioned in this paper investigated long-term safety and efficacy of treatment in patients with severe COVID-19 patients who had received hUC-MSC therapy, and they found that the hUCMSC had a positive effect on post-infection sequelae in COVID19 survivors.